Xiong S, Huang L, Liu H, Zhang X, Li M, Cui Y
World J Diabetes. 2025; 16(2):97287.
PMID: 39959262
PMC: 11718488.
DOI: 10.4239/wjd.v16.i2.97287.
Youm E, Shipman K, Albalawy W, Vandevender A, Sipula I, Rbaibi Y
Function (Oxf). 2024; 5(4).
PMID: 38984983
PMC: 11237895.
DOI: 10.1093/function/zqae026.
Zhang S, Zhu X, Chen Y, Wen Z, Shi P, Ni Q
Front Immunol. 2024; 15:1393392.
PMID: 38774880
PMC: 11106398.
DOI: 10.3389/fimmu.2024.1393392.
Kani R, Watanabe A, Miyamoto Y, Ejiri K, Iwagami M, Takagi H
J Am Heart Assoc. 2024; 13(3):e031805.
PMID: 38293914
PMC: 11056162.
DOI: 10.1161/JAHA.123.031805.
Hu Y, Bao J, Gao Z, Ye L, Wang L
Diabetes Metab Syndr Obes. 2024; 17:407-415.
PMID: 38292009
PMC: 10826576.
DOI: 10.2147/DMSO.S446904.
Outcomes of Prediabetes Compared with Normoglycaemia and Diabetes Mellitus in Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis.
Ahsan M, Latif A, Ahmad S, Willman C, Lateef N, Shabbir M
Heart Int. 2023; 17(1):45-53.
PMID: 37456347
PMC: 10339437.
DOI: 10.17925/HI.2023.17.1.45.
An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease.
Sun D, Targher G, Byrne C, Wheeler D, Wong V, Fan J
Hepatobiliary Surg Nutr. 2023; 12(3):386-403.
PMID: 37351121
PMC: 10282675.
DOI: 10.21037/hbsn-22-421.
Impact of sodium-glucose co-transporter 2 inhibitors on renal outcomes in patients of diabetes mellitus: A meta-analysis of landmark renal and cardiovascular outcome trials.
Bose D, Maurya M, Konwar M
Indian J Pharmacol. 2023; 55(2):119-127.
PMID: 37313937
PMC: 10335648.
DOI: 10.4103/ijp.ijp_342_21.
SGLT-2 Inhibitors and the Inflammasome: What's Next in the 21st Century?.
Kounatidis D, Vallianou N, Evangelopoulos A, Vlahodimitris I, Grivakou E, Kotsi E
Nutrients. 2023; 15(10).
PMID: 37242177
PMC: 10221012.
DOI: 10.3390/nu15102294.
The SGLT2 Inhibitor Canagliflozin Reduces Atherosclerosis by Enhancing Macrophage Autophagy.
Chen H, Teng D, Xu B, Wang C, Wang H, Jia W
J Cardiovasc Transl Res. 2023; 16(5):999-1009.
PMID: 37126209
DOI: 10.1007/s12265-023-10390-w.
Emerging Role of Sodium-Glucose Co-Transporter 2 Inhibitors for the Treatment of Chronic Kidney Disease.
Isidto R, Danguilan R, Naidas O, Vilanueva R, Arakama M, Paraiso L
Int J Nephrol Renovasc Dis. 2023; 16:43-57.
PMID: 36852177
PMC: 9960786.
DOI: 10.2147/IJNRD.S387262.
Biomolecular Mechanisms of Cardiorenal Protection with Sodium-Glucose Co-Transporter 2 Inhibitors.
Prandi F, Barone L, Lecis D, Belli M, Sergi D, Milite M
Biomolecules. 2022; 12(10).
PMID: 36291558
PMC: 9599693.
DOI: 10.3390/biom12101349.
Value of SGLT-2 inhibitors in the treatment of chronic kidney disease : Clinical and practical implications.
Saemann M, Cejka D, Schmaldienst S, Rosenkranz A, Mayer G
Wien Klin Wochenschr. 2022; 135(3-4):97-109.
PMID: 36251099
DOI: 10.1007/s00508-022-02096-x.
Canagliflozin Ameliorates Nonalcoholic Fatty Liver Disease by Regulating Lipid Metabolism and Inhibiting Inflammation through Induction of Autophagy.
Xu Z, Hu W, Wang B, Xu T, Wang J, Wei D
Yonsei Med J. 2022; 63(7):619-631.
PMID: 35748073
PMC: 9226837.
DOI: 10.3349/ymj.2022.63.7.619.
An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors.
Salvatore T, Galiero R, Caturano A, Rinaldi L, di Martino A, Albanese G
Int J Mol Sci. 2022; 23(7).
PMID: 35409011
PMC: 8998569.
DOI: 10.3390/ijms23073651.
Role of Erythropoiesis-Stimulating Agents in Cardiovascular Protection in CKD Patients: Reappraisal of Their Impact and Mechanisms.
Miura T, Sato T, Yano T, Takaguri A, Miki T, Tohse N
Cardiovasc Drugs Ther. 2022; 37(6):1175-1192.
PMID: 35150385
DOI: 10.1007/s10557-022-07321-3.
Association of metabolic dysfunction-associated fatty liver disease with kidney disease.
Wang T, Wang R, Bu Z, Targher G, Byrne C, Sun D
Nat Rev Nephrol. 2022; 18(4):259-268.
PMID: 35013596
DOI: 10.1038/s41581-021-00519-y.
Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations.
Noels H, Lehrke M, Vanholder R, Jankowski J
Nat Rev Nephrol. 2021; 17(8):528-542.
PMID: 33972752
DOI: 10.1038/s41581-021-00423-5.
Key metalloproteinase-mediated pathways in the kidney.
Wozniak J, Floege J, Ostendorf T, Ludwig A
Nat Rev Nephrol. 2021; 17(8):513-527.
PMID: 33879883
DOI: 10.1038/s41581-021-00415-5.
SGLT2 inhibitors break the vicious circle between heart failure and insulin resistance: targeting energy metabolism.
Wang X, Ni J, Guo R, Li L, Su J, He F
Heart Fail Rev. 2021; 27(3):961-980.
PMID: 33713009
DOI: 10.1007/s10741-021-10096-8.
